Harmony Biosciences Holdings, Inc. — Form 8-K Summary
Business context and reporting period
This Form 8-K reports corporate governance and executive-compensation matters. The earliest reported event occurred on November 18, 2021; the filing was signed November 22, 2021. Harmony Biosciences is listed on Nasdaq under the symbol HRMY.
Key financial metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating and financial metrics.
Material changes
- Effective November 18, 2021, Linda Szyper was appointed as a Class II director, filling the vacancy created by Eric L. Motley’s resignation effective August 30, 2021.
- Ms. Szyper was appointed to the Nominating and Corporate Governance Committee.
- Her term runs through the 2022 Annual Meeting of Stockholders, subject to earlier termination under applicable circumstances.
- The Board determined that Ms. Szyper is independent under Nasdaq governance standards.
Compensation, outlook, and risks
- Ms. Szyper will receive compensation consistent with the company’s non-employee director compensation program.
- The company will enter into its standard director indemnification agreement with Ms. Szyper.
- The filing discloses no financial guidance, operating outlook, material contingencies, or unusual financial items.
- The company stated that Ms. Szyper was selected for her experience in pharmaceutical marketing, medical communications, consumer health, and payer and patient engagement.
Investor verification points
- Verify the final composition of the Board and committee assignments following the 2022 annual meeting.
- Review the company’s director compensation program and indemnification agreement.
- Confirm that the November 22, 2021 press release furnished as Exhibit 99.1 contains no additional material information.
- Use the company’s periodic reports for financial performance, liquidity, debt, guidance, and risk disclosures, which are not included in this filing.